Key Takeaways The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead ...

Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks ...

Eli Lilly (LLY) closed at $773.84 in the latest trading session, marking a -1.19% move from the prior day. The stock's change was less than the S&P 500's daily loss of 1.07%. At the same time ...

Lilly now expects fourth-quarter sales of $3.5 billion for diabetes drug Mounjaro and $1.9 billion for Zepbound. That is much higher than a year earlier but Explore Our Brands ...

2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE ... outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so ...

Shares of pharmaceutical stock Eli Lilly are cratering after the company lowered its sales guidance for Q4. All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq ...